-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-08-03
Values as of: 2024-08-03
The investment seeks to track the performance of a benchmark index. The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the Global Industry Classification Standard (GICS). The Advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.
Company Website : www.vanguard.com
Currency: USD
Country : USA
Inception Date: 26/01/2004
Primary Benchmark: MSCI US IMI/Health Care 25-50 GR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.1%
Management Expense Ratio: 0.10 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
N/A |
USD 42.49B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
N/A |
USD 3.19B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
N/A |
USD 1.30B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
N/A |
USD 0.23B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
N/A |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
N/A |
USD 0.11B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
N/A |
USD 0.09B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
N/A |
USD 0.06B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
N/A |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
N/A |
USD 0.01B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| BSR | Northern Lights Fund Trus.. | 8.81 % | 0.00 % |
N/A |
N/A |
| BTR | Northern Lights Fund Trus.. | 8.81 % | 0.00 % |
N/A |
N/A |
| QLS | 0.00 % | 0.76 % |
N/A |
N/A | |
| QPX | AdvisorShares Q Dynamic G.. | 0.00 % | 0.00 % |
N/A |
USD 0.03B |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 10.06% | 71% | C- | 75% | C | ||
| Dividend Return | 0.33% | 47% | F | 6% | D- | ||
| Total Return | 10.38% | 67% | D+ | 70% | C- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 13.29% | 62% | D | 73% | C | ||
| Dividend Return | 1.06% | 61% | D- | 14% | F | ||
| Total Return | 14.36% | 62% | D | 67% | D+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 65.41% | 90% | A- | 78% | C+ | ||
| Dividend Return | 8.07% | 89% | A- | 25% | F | ||
| Total Return | 73.49% | 90% | A- | 77% | C+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 9.21% | 81% | B- | 68% | D+ | ||
| Dividend Return | 10.51% | 90% | A- | 65% | D | ||
| Total Return | 1.30% | 95% | A | 30% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 12.40% | 76% | C+ | 71% | C- | ||
| Risk Adjusted Return | 84.72% | 86% | B+ | 94% | A | ||
| Market Capitalization | 5.43B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
There is nothing we particularly dislike
